Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 11/20 | 0.65 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329279 | 0.86 | NR4A2 (0.48) | NR4A2CREBBPMAP2K1KDM4EALDH1A1 | |
| SCHEMBL5409892 | 0.83 | ALDH1A1 (0.54) | NR4A2CREBBPMAP2K1KDM4EALDH1A1 | |
| SCHEMBL22462638 | 0.81 | MAPT (0.65) | NR4A2CREBBPMAP2K1KDM4EALDH1A1 | |
| SCHEMBL2036909 | 0.79 | NR4A2 (1.00) | NR4A2CREBBPMAP2K1KDM4EALDH1A1 | |
| SCHEMBL2040417 | 0.78 | NR4A2 (1.00) | NR4A2CREBBPMAP2K1KDM4EALDH1A1 | |
| SCHEMBL17113293 | 0.78 | NR4A2 (0.70) | NR4A2CREBBPMAP2K1KDM4EALDH1A1 | |
| SCHEMBL2034149 | 0.78 | NR4A2 (0.70) | NR4A2CREBBPMAP2K1KDM4EALDH1A1 | |
| SCHEMBL9936554 | 0.78 | NR4A2 (0.70) | NR4A2CREBBPMAP2K1KDM4EALDH1A1 | |
| SCHEMBL2647337 | 0.77 | ALDH1A1 (0.47) | NR4A2CREBBPKDM4EALDH1A1HPGD | |
| SCHEMBL15388930 | 0.77 | NR4A2 (0.63) | NR4A2CREBBPMAP2K1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | NR4A2 3995/4885CREBBP 3960/4885MAP2K1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.